STRONG Trial Tests Blueberries, Protein and Exercise Against Frailty in Older Adults
A Canadian RCT combining daily blueberries, protein powder, and supervised exercise aims to cut frailty and cardiovascular risk in adults 65+.
Summary
The STRONG trial is a one-year randomized controlled trial enrolling 240 Nova Scotians aged 65 and older to test whether a combined lifestyle intervention — one cup of blueberries per day, 30 g of daily protein powder, and three supervised multimodal exercise sessions per week — can reduce frailty and improve cardiovascular health. Half the participants receive the full intervention; the other half receive usual care. Outcomes tracked include frailty scores, balance, falls, blood pressure, lipid profiles, cardiac function, inflammatory markers, physical fitness, and quality of life, measured at baseline and at 3, 6, 9, 12, and 24 months. The trial is built on prior evidence that exercise reduces frailty and that blueberries improve vascular health and suppress cellular senescence. Results could offer a practical, low-cost blueprint for clinicians managing older patients at cardiovascular risk.
Detailed Summary
Frailty and cardiovascular disease are tightly intertwined in older adults, yet most clinical interventions address one without targeting the other. The STRONG trial was designed to close that gap by combining three evidence-informed lifestyle strategies into a single, pragmatic year-long intervention.
Researchers at Dalhousie University are enrolling 240 community-dwelling adults aged 65 and older — 120 women and 120 men — in Nova Scotia, Canada. Participants are randomized to either the STRONG intervention (one cup of blueberries daily, 30 g of protein powder daily, and three 60-minute multimodal exercise sessions per week with an exercise physiologist) or usual care. A 12-month follow-up period extends observation to two years total.
The rationale draws on converging lines of evidence. Exercise, particularly resistance and multimodal training, has consistently reduced frailty scores in older adults. Dietary protein attenuates sarcopenia, the muscle loss that underlies much of frailty's physical component. Blueberries, rich in anthocyanins and polyphenols, have demonstrated vascular benefits and senolytic-adjacent properties, potentially reducing the cellular senescence burden that accelerates both frailty and cardiovascular aging.
Outcomes span frailty measures (including the validated frailty index, balance tests, fall rates, and life-space mobility), cardiovascular risk factors (blood pressure, lipid profiles, Framingham risk score), cardiac function, inflammatory markers, physical fitness, diet quality, and health-related quality of life. This comprehensive measurement strategy allows investigators to determine whether frailty reductions translate into measurable cardiovascular benefit.
If the intervention proves effective, it could offer clinicians a concrete, low-barrier prescription — real food, standard protein supplementation, and structured exercise — applicable across primary care and geriatric settings. Caveats include the pragmatic open-label design, the relatively small sample size, and the fact that this is a protocol paper — no outcome data are yet available.
Key Findings
- 240 adults aged 65+ will be randomized to a combined blueberry, protein, and exercise intervention versus usual care for one year.
- The intervention includes 1 cup of blueberries daily, 30 g protein powder, and three 60-minute supervised exercise sessions per week.
- Primary outcomes target both frailty reduction and cardiovascular risk improvement simultaneously, a novel dual focus.
- Blueberries are included for their evidence in improving vascular health and suppressing cellular senescence in older adults.
- A 24-month total observation period will assess whether benefits are sustained after the active intervention ends.
Methodology
STRONG is a parallel-group, open-label, randomized controlled superiority trial enrolling 240 older adults (120 female, 120 male, aged ≥65) in Nova Scotia, Canada. The intervention lasts 12 months with an additional 12-month passive follow-up; outcomes are assessed at baseline and at 3, 6, 9, 12, and 24 months. The trial follows CONSORT and SPIRIT reporting guidelines and is registered as NCT06693271.
Study Limitations
This is a protocol publication only; no efficacy or outcome data are yet available, so the summary is based on the abstract and study design alone. The open-label design means blinding of participants and exercise physiologists is not feasible, introducing potential performance and assessment bias. The sample size of 240 may limit power to detect modest effects across the multiple secondary outcomes examined.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: